{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:15Z","timestamp":1781626035461,"version":"3.54.5"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV and Hepatitis C (HCV) are blood borne infections (BBIs) that remain a significant cause of global morbidity and mortality among people who inject drugs (PWID). UNAIDS and WHO have set goals for the elimination of viral hepatitis and HIV as major public health threats by 2030. To achieve these targets, innovative strategies are required among marginalized populations such as PWID, especially in resource-limited countries where coverage of harm reduction services is often limited. The goal of this study is to inform targeted strategies to prevent transmission of BBIs among PWID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We will use respondent driven sampling (RDS) to recruit PWID from needle and syringe programs in Kenya. Participants will complete biobehavioral and social network surveys and receive point-of-care HCV, HIV, and hepatitis B (HBV) testing. Participants will return for at least one follow-up visit to complete additional surveys and testing. We will use network data from RDS, egocentric, and viral phylogenetics to identify how highly central PWID contribute to transmission networks and use mathematical modelling to investigate the impact of targeted interventions based on network characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will provide important information for policymakers and researchers designing strategies for BBI elimination. Network- and molecular epidemiologic-informed tools to guide targeted strategies may be critical to maximizing the impact of treatment and prevention efforts in resource-limited settings. This approach may provide a durable template for future studies, including prospective assessments of targeted prevention and elimination strategies among PWID, and assist with monitoring elimination progress in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12035-6","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:24:17Z","timestamp":1766132657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leveraging injection networks to prevent HIV and other blood borne infections among people who inject drugs in Kenya: design and rationale"],"prefix":"10.1186","volume":"25","author":[{"given":"Matthew J.","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah N.","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Riback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Alvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Gile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Nyakowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issak","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine G.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"5","key":"12035_CR1","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2214-109X(23)00057-8","volume":"11","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. The Lancet Global Health. 2023;11(5):e659\u201372.","journal-title":"The Lancet Global Health"},{"key":"12035_CR2","unstructured":"Joint United Nations programme on HIV\/AIDS (UNAIDS), The urgency of now: AIDS at a crossroads. Geneva, Switzerland: Global AIDS; 2024."},{"key":"12035_CR3","volume-title":"Health, rights, and drugs: harm reduction, decriminization, and zero discrimination for people who use drugs","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2019","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). Health, rights, and drugs: harm reduction, decriminization, and zero discrimination for people who use drugs. 2019."},{"key":"12035_CR4","unstructured":"Joint United Nations programme on HIV\/AIDS (UNAIDS). Global AIDS targets 2025 for people who use drugs: where are we now?, Joint United Nations programme on HIV\/AIDS (UNAIDS). Geneva, Switzerland; 2024."},{"issue":"12","key":"12035_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","volume":"2","author":"MW Sonderup","year":"2017","unstructured":"Sonderup MW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al. Hepatitis C in Sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol Hepatol. 2017;2(12):910\u201319.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"12035_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(18)30413-8","volume":"4","author":"CW Spearman","year":"2019","unstructured":"Spearman CW, Sonderup MW. Direct-acting antiviral therapy in Sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2019;4(2):85\u201386.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"12035_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S2468-1253(23)00335-7","volume":"9","author":"AD Marshall","year":"2024","unstructured":"Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O\u2019Brien N, et al. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions. The Lancet Gastroenterol Hepatol. 2024;9(4):366\u201382.","journal-title":"The Lancet Gastroenterol Hepatol"},{"key":"12035_CR8","doi-asserted-by":"crossref","unstructured":"Hajarizadeh B, Kairouz A, Ottaviano S, Ireland J, Willing A, Cunningham E, et al. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review. The Lancet Global Health. 20231898;11(12):e1885\u2013e.","DOI":"10.1016\/S2214-109X(23)00461-8"},{"key":"12035_CR9","doi-asserted-by":"crossref","unstructured":"Stevens O, Sabin K, Anderson RL, Garcia SA, Willis K, Rao A, et al. Population size, HIV prevalence, and antiretroviral therapy coverage among key populations in sub-saharan Africa: collation and synthesis of survey data, 2010-23. Lancet Glob Health. 20241412;12(9):e1400\u2013e.","DOI":"10.1016\/S2214-109X(24)00236-5"},{"key":"12035_CR10","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. 2024, World Health Organization, Geneva, Switzerland."},{"key":"12035_CR11","unstructured":"National AIDS and STI control programme, key population size estimates in Kenya Final report, 2020. 2021, Ministry of Health, Kenya, Nairobi, Kenya."},{"issue":"11","key":"12035_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S1473-3099(19)30264-6","volume":"19","author":"MJ Akiyama","year":"2019","unstructured":"Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. Lancet Infect Dis. 2019;19(11):1255\u201363.","journal-title":"Lancet Infect Dis"},{"key":"12035_CR13","volume-title":"Harm reduction financing in Kenya: advocacy for local resource allocation","author":"Harm Reduction International","year":"2021","unstructured":"Harm Reduction International. Harm reduction financing in Kenya: advocacy for local resource allocation. 2021."},{"key":"12035_CR14","volume-title":"Consolidated guidelines on HIV, viral hepatitis and sti prevention, diagnosis, treatment and care for key populations","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Consolidated guidelines on HIV, viral hepatitis and sti prevention, diagnosis, treatment and care for key populations. 2022."},{"key":"12035_CR15","volume-title":"National implementation guidelines for medically assisted therapy for people with opioid use disorders","author":"National AIDS and STI Control Programme (NASCOP)","year":"2021","unstructured":"National AIDS and STI Control Programme (NASCOP). National implementation guidelines for medically assisted therapy for people with opioid use disorders. Nairobi, Kenya: Kenya Ministry of Health; 2021."},{"key":"12035_CR16","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.drugpo.2025.104824","volume":"140","author":"JG Walker","year":"2025","unstructured":"Walker JG, Akiyama MJ, Artenie A, Cleland CM, Lizcano JA, Musyoki H, et al. Impact of scaling up harm reduction interventions on injecting risk behaviours, art outcomes and HIV incidence among people who inject drugs in Kenya. Int J Drug Policy. 2025;140:104824.","journal-title":"Int J Drug Policy"},{"key":"12035_CR17","unstructured":"Government of Kenya, Gastroenterology society of Kenya, guidelines for the treatment of chronic hepatitis B and C viral infections in Kenya. 2016."},{"issue":"8","key":"12035_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/jvh.13662","volume":"29","author":"MJ Akiyama","year":"2022","unstructured":"Akiyama MJ, Riback LR, Nyakowa M, Musyoki H, Lizcano JA, Muller A, et al. Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya. J Viral Hepat. 2022;29(8):691\u201394.","journal-title":"J Viral Hepat"},{"key":"12035_CR19","doi-asserted-by":"publisher","first-page":"103959","DOI":"10.1016\/j.drugpo.2023.103959","volume":"113","author":"MJ Akiyama","year":"2023","unstructured":"Akiyama MJ, Riback LR, Nyakowa M, Musyoki H, Lizcano JA, Muller A, et al. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya. Int J Drug Policy. 2023;113:103959.","journal-title":"Int J Drug Policy"},{"issue":"15","key":"12035_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1097\/QAD.0000000000003382","volume":"36","author":"J Stone","year":"2022","unstructured":"Stone J, Fraser H, Walker JG, Mafirakureva N, Mundia B, Cleland C, et al. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya. Aids. 2022;36(15):2191\u2013201.","journal-title":"Aids"},{"issue":"2","key":"12035_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/add.15630","volume":"117","author":"N Mafirakureva","year":"2022","unstructured":"Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A, Thiong\u2019o AW, et al. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. Addiction. 2022;117(2):411\u201324.","journal-title":"Addiction"},{"issue":"Suppl 3","key":"12035_CR22","doi-asserted-by":"publisher","first-page":"e25729","DOI":"10.1002\/jia2.25729","volume":"24","author":"H Musyoki","year":"2021","unstructured":"Musyoki H, Bhattacharjee P, Sabin K, Ngoksin E, Wheeler T, Dallabetta G. A decade and beyond: learnings from HIV programming with underserved and marginalized key populations in Kenya. J Int AIDS Soc. 2021;24 (Suppl 3):e25729.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"12035_CR23","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","volume":"11","author":"S Colledge-Frisby","year":"2023","unstructured":"Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. The Lancet Global Health. 2023;11(5):e673\u201383.","journal-title":"The Lancet Global Health"},{"key":"12035_CR24","unstructured":"Harm Reduction International, Harm reduction financing in Kenya: advocacy for local resource allocation, 2021."},{"key":"12035_CR25","unstructured":"Harm Reduction International. Impact of PEPFAR funding cuts in harm reduction in Kenya. 2025."},{"key":"12035_CR26","unstructured":"Joint United Nations programme on HIV\/AIDS (UNAIDS). Impact of US funding freeze on HIV programmes in Kenya. 2025."},{"key":"12035_CR27","volume-title":"Kenya\u2019s health system in crisis: the fallout of the U.S. foreign aid freeze, from freeze to evisceration of U.S","author":"J Kosgei","year":"2025","unstructured":"Kosgei J. Kenya\u2019s health system in crisis: the fallout of the U.S. foreign aid freeze, from freeze to evisceration of U.S. Foreign Aid Webinar; 2025."},{"issue":"4","key":"12035_CR28","doi-asserted-by":"publisher","first-page":"e26241","DOI":"10.1002\/jia2.26241","volume":"27","author":"NS Prata Menezes","year":"2024","unstructured":"Prata Menezes NS, Mehta SH, Wesolowski A, Clipman SJ, Srikrishnan AK, Kumar MS, et al. Injection network drivers of HIV prevention service utilization among people who inject drugs: results of a community-based sociometric network cohort in New Delhi, India. J Int AIDS Soc. 2024;27(4):e26241.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"12035_CR29","first-page":"1782","volume":"74","author":"SJ Clipman","year":"2021","unstructured":"Clipman SJ, Mehta SH, Rodgers MA, Duggal P, Srikrishnan AK, Saravanan S, et al. Spatiotemporal Phylodynamics of Hepat C Among People Who Inject Drugs in India, Hepatol. 2021;74(4):1782\u201394.","journal-title":"Spatiotemporal Phylodynamics Of Hepat C Among People Who Inject Drugs In India, Hepatol"},{"key":"12035_CR30","doi-asserted-by":"crossref","unstructured":"Clipman SJ, Mehta SH, Srikrishnan AK, Zook KJ, Duggal P, Mohapatra S, et al. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India. Elife. 2021;10.","DOI":"10.7554\/eLife.69174"},{"issue":"3","key":"12035_CR31","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/add.16379","volume":"119","author":"NS Prata Menezes","year":"2024","unstructured":"Prata Menezes NS, Mehta SH, Wesolowski A, Clipman SJ, Srikrishnan AK, Kumar MS, et al. Network centrality and HIV prevention service use among people who inject drugs: findings from a sociometric network cohort in New Delhi, India. Addiction. 2024;119(3):570\u201381.","journal-title":"Addiction"},{"issue":"9","key":"12035_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jvh.13960","volume":"31","author":"SJ Clipman","year":"2024","unstructured":"Clipman SJ, Mehta SH, Mohapatra S, Srikrishnan AK, Zook KJC, Kumar MS, et al. Network-based strategies to combat HCV: examining social and spatial drivers of transmission among PWID in New Delhi. J Viral Hepat. 2024;31(9):535\u201343.","journal-title":"J Viral Hepat"},{"key":"12035_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.drugalcdep.2015.06.042","volume":"154","author":"B Boodram","year":"2015","unstructured":"Boodram B, Mackesy-Amiti ME, Latkin C. The role of social networks and geography on risky injection behaviors of young persons who inject drugs. Drug Alcohol Depend. 2015;154:229\u201335.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"12035_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2105\/AJPH.87.8.1289","volume":"87","author":"SR Friedman","year":"1997","unstructured":"Friedman SR, Neaigus A, Jose B, Curtis R, Goldstein M, Ildefonso G, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289\u201396.","journal-title":"Am J Public Health"},{"key":"12035_CR35","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1017\/S095026881900061X","volume":"147","author":"T Spelman","year":"2019","unstructured":"Spelman T, Sacks-Davis R, Dietze P, Higgs P, Hellard M. Injection drug network characteristics as a predictor of injection behaviour. Epidemiol Infect. 2019;147:e173.","journal-title":"Epidemiol Infect"},{"issue":"5","key":"12035_CR36","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.socscimed.2004.12.024","volume":"61","author":"T Rhodes","year":"2005","unstructured":"Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sciamp; Med. 2005;61(5):1026\u201344.","journal-title":"Soc Sciamp; Med"},{"issue":"10","key":"12035_CR37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.drugpo.2015.05.006","volume":"26","author":"M Hellard","year":"2015","unstructured":"Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, et al. Hepatitis C transmission and treatment as prevention \u2013 the role of the injecting network. Int J Multiling Drug Policy. 2015;26(10):958\u201362.","journal-title":"Int J Multiling Drug Policy"},{"key":"12035_CR38","volume-title":"Geographic variability in harm reduction uptake, risk behaviors, and network characteristics among people who inject drugs in Kenya: a key hurdle to hepatitis C elimination","author":"H Manley","year":"2024","unstructured":"Manley H, Riback L, Nyakowa M, Zhang C, Wafula R, Ganatra N, et al. Geographic variability in harm reduction uptake, risk behaviors, and network characteristics among people who inject drugs in Kenya: a key hurdle to hepatitis C elimination. Milan, Italy: European Association for the Study of the Liver; 2024."},{"key":"12035_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.meegid.2015.04.017","volume":"33","author":"AD Olmstead","year":"2015","unstructured":"Olmstead AD, Joy JB, Montoya V, Luo I, Poon AF, Jacka B, et al. A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events. Infect Genet Evol. 2015;33:101\u201309.","journal-title":"Infect Genet Evol"},{"issue":"5","key":"12035_CR40","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","volume":"136","author":"T van de Laar","year":"2009","unstructured":"van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009;136(5):1609\u201317.","journal-title":"Gastroenterology"},{"key":"12035_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.meegid.2018.05.028","volume":"63","author":"DS Campo","year":"2018","unstructured":"Campo DS, Khudyakov Y. Intelligent network DisRuption analysis (indra): a targeted strategy for efficient interruption of hepatitis C transmissions. Infect Genet Evol. 2018;63:204\u201315.","journal-title":"Infect Genet Evol"},{"key":"12035_CR42","doi-asserted-by":"crossref","unstructured":"Ramachandran S, Thai H, Forbi JC, Galang RR, Dimitrova Z, Xia GL, et al. A large HCV transmission network enabled a fast-growing HIV outbreak in rural Indiana. EBioMedicine. 2015 (2018;37:374\u201381.","DOI":"10.1016\/j.ebiom.2018.10.007"},{"issue":"8","key":"12035_CR43","doi-asserted-by":"publisher","first-page":"e0256601","DOI":"10.1371\/journal.pone.0256601","volume":"16","author":"J Grubb","year":"2021","unstructured":"Grubb J, Lopez D, Mohan B, Matta J. Network centrality for the identification of biomarkers in respondent-driven sampling datasets. PLoS One. 2021;16(8):e0256601.","journal-title":"PLoS One"},{"issue":"4","key":"12035_CR44","first-page":"213","volume":"4","author":"LJ Semaan S.","year":"2002","unstructured":"Semaan S. LJ, Liebman J. Street and network sampling in evaluation studies of HIV risk-reduction interventions. AIDS Rev. 2002;4(4):213\u201323.","journal-title":"AIDS Rev"},{"issue":"3","key":"12035_CR45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11524-006-9052-7","volume":"83","author":"AQ Abdul","year":"2006","unstructured":"Abdul AQ, Heckathorn D, McKnight C, Bramson H, Nemeth C, Sabin K, et al. Effectiveness of respondent-driven sampling for recruiting Drug users in New York City: findings from a Pilot study. J Urban Health. 2006;83(3):459\u201376.","journal-title":"J Urban Health"},{"issue":"1","key":"12035_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1467-9531.2007.00188.x","volume":"37","author":"DD Heckathorn","year":"2007","unstructured":"Heckathorn DD. Extensions of respondent-driven sampling: analyzing continuous variables and controlling for differential recruitment. Sociological Methodol. 2007;37(1):151\u2013207.","journal-title":"Sociological Methodol"},{"issue":"2","key":"12035_CR47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2307\/3096941","volume":"44","author":"DD Heckathorn","year":"1997","unstructured":"Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174\u201399.","journal-title":"Soc Probl"},{"issue":"4","key":"12035_CR48","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/QAI.0000000000000769","volume":"70","author":"AE Kurth","year":"2015","unstructured":"Kurth AE, Cleland CM, Des Jarlais DC, Musyoki H, Lizcano JA, Chhun N, et al. HIV prevalence, estimated incidence, and risk behaviors among people who inject drugs in Kenya. J Acquir Immune Defic Syndr. 2015;70(4):420\u201327.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"12035_CR49","unstructured":"National institute on Drug abuse, seek, test, treat and retain for vulnerable populations: data harmonization measure-HIV Risk Measure. National Institue on Drug Abuse; 2013."},{"key":"12035_CR50","unstructured":"National institute on Drug abuse, seek, test, treat and retain for vulnerable populations: data harmonization measure- Drug and alcohol measure. Natl Institue on Drug Abuse. 2013."},{"issue":"8","key":"12035_CR51","first-page":"439","volume":"91","author":"SC Kalichman","year":"1999","unstructured":"Kalichman SC, Catz S, Ramachandran B. Barriers to HIV\/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc. 1999;91(8):439\u201346.","journal-title":"J Natl Med Assoc"},{"key":"12035_CR52","unstructured":"National institute on Drug abuse, seek, test, treat and retain for vulnerable populations: data harmonization measure - service utilization (Adherence) measure. Natl Institue on Drug Abuse. 2013."},{"issue":"10","key":"12035_CR53","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"12035_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2016.02.019","volume":"162","author":"LR Smith","year":"2016","unstructured":"Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance use stigma: reliability and validity of a theory-based scale for substance-using populations. Drug Alcohol Depend. 2016;162:34\u201343.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"12035_CR55","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1080\/17441692.2021.1896763","volume":"17","author":"MJ Akiyama","year":"2022","unstructured":"Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, et al. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: a qualitative study. Glob Public Health. 2022;17(6):1016\u201328.","journal-title":"Glob Public Health"},{"key":"12035_CR56","unstructured":"National AIDS and STI Control Programme (NASCOP). National guidelines for the control and management of viral hepatitis. Kenya Ministry of Health. 2018."},{"key":"12035_CR57","unstructured":"National AIDS and STI control programme (NASCOP), Kenya hiv prevention and treatment guidelines, 2022. Nairobi, Kenya: Ministry of Health Kenya; 2022."},{"key":"12035_CR58","unstructured":"National AIDS and STI control programme (NASCOP). In: The Kenya HIV testing services operational manual, Kenya ministry of health. Nairobi, Kenya; 2022."},{"key":"12035_CR59","unstructured":"Kenya\u2019s ministry of health advances HIV testing precision and affirms commitment to quality services. Kenya Ministry of Health; 2024."},{"issue":"3","key":"12035_CR60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.drugpo.2008.10.003","volume":"20","author":"T Rhodes","year":"2009","unstructured":"Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20(3):193\u2013201.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"12035_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0955-3959(02)00007-5","volume":"13","author":"T Rhodes","year":"2002","unstructured":"Rhodes T. The \u2018risk environment\u2019: a framework for understanding and reducing drug-related harm. Int J Multiling Drug Policy. 2002;13(2):85\u201394.","journal-title":"Int J Multiling Drug Policy"},{"key":"12035_CR62","doi-asserted-by":"crossref","unstructured":"Kim D, Gile K, Guarino H, Mateu-Gelabert P. Inferring bivariate association from respondent-driven sampling data. J Educ Chang The R Stat Soc: Ser C (appl Stat). 2021;70.","DOI":"10.1111\/rssc.12465"},{"issue":"6","key":"12035_CR63","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/infdis\/jiv542","volume":"213","author":"DS Campo","year":"2016","unstructured":"Campo DS, Xia GL, Dimitrova Z, Lin Y, Forbi JC, Ganova-Raeva L, et al. Accurate genetic detection of hepatitis C virus transmissions in outbreak settings. The J Infect Dis. 2016;213(6):957\u201365.","journal-title":"The J Infect Dis"},{"issue":"9","key":"12035_CR64","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1177\/09622802211032713","volume":"30","author":"M Yauck","year":"2021","unstructured":"Yauck M, Moodie EE, Apelian H, Fourmigue A, Grace D, Hart T, et al. General regression methods for respondent-driven sampling data. Stat Methods Med Res. 2021;30(9):2105\u201318.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"12035_CR65","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/infdis\/jiz058","volume":"220","author":"J Leung","year":"2019","unstructured":"Leung J, Peacock A, Colledge S, Grebely J, Cunningham EB, Hickman M, et al. A global meta-analysis of the prevalence of HIV, hepatitis C virus, and hepatitis B virus among people who inject drugs-do gender-based differences vary by country-level indicators? The J Infect Dis. 2019;220(1):78\u201390.","journal-title":"The J Infect Dis"},{"issue":"6","key":"12035_CR66","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S2468-1253(23)00018-3","volume":"8","author":"A Artenie","year":"2023","unstructured":"Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim AG, et al. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):533\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12035_CR67","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2164-15-S5-S4","volume":"15 Suppl 5","author":"DS Campo","year":"2014","unstructured":"Campo DS, Dimitrova Z, Yamasaki L, Skums P, Lau DT, Vaughan G, et al. Next-generation sequencing reveals large connected networks of intra-host HCV variants. BMC Genomics. 2014;15 Suppl 5:S4.","journal-title":"BMC Genomics"},{"key":"12035_CR68","doi-asserted-by":"crossref","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 20171207;5(12):e1192\u2013e.","DOI":"10.1016\/S2214-109X(17)30375-3"},{"issue":"7","key":"12035_CR69","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1360-0443.2006.01431.x","volume":"101","author":"EC Costenbader","year":"2006","unstructured":"Costenbader EC, Astone NM, Latkin CA. The dynamics of injection drug users\u2019 personal networks and HIV risk behaviors. Addiction. 2006;101(7):1003\u201313.","journal-title":"Addiction"},{"issue":"6 Suppl","key":"12035_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10461-007-9238-3","volume":"11","author":"D German","year":"2007","unstructured":"German D, Davey MA, Latkin CA. Residential transience and HIV risk behaviors among injection drug users. AIDS Behav. 2007;11(6 Suppl):21\u201330.","journal-title":"AIDS Behav"},{"issue":"4","key":"12035_CR71","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11524-011-9574-5","volume":"88","author":"E Roy","year":"2011","unstructured":"Roy E, Robert M, Vaillancourt E, Boivin JF, Vandermeerschen J, Martin I. Residential trajectory and HIV high-risk behaviors among Montr\u00e9al street youth\u2013a reciprocal relationship. J Urban Health. 2011;88(4):767\u201378.","journal-title":"J Urban Health"},{"key":"12035_CR72","doi-asserted-by":"publisher","first-page":"107215","DOI":"10.1016\/j.ijid.2024.107215","volume":"147","author":"MJ Akiyama","year":"2024","unstructured":"Akiyama MJ, Khudyakov Y, Ramachandran S, Riback LR, Ackerman M, Nyakowa M, et al. Widespread hepatitis C virus transmission network among people who inject drugs in Kenya. Int J Infect Dis. 2024;147:107215.","journal-title":"Int J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12035-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:26:49Z","timestamp":1781623609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12035-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12035"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12035-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Albert Einstein College of Medicine Institutional Review Board (IRB# 2021\u2013 12,928) and the Kenyatta National Hospital Ethics and Research Committee (ERC; University of Nairobi; IRB# P856\/10\/2021). Formal informed consent will be obtained from all study participants and participation is strictly voluntary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1726"}}